Title |
Endogenous cardiac stem cells for the treatment of heart failure
|
---|---|
Published in |
Stem cells and cloning advances and applications, March 2013
|
DOI | 10.2147/sccaa.s29221 |
Pubmed ID | |
Authors |
Tania Fuentes, Mary Kearns-Jonker |
Abstract |
Stem cell-based therapies hold promise for regenerating the myocardium after injury. Recent data obtained from phase I clinical trials using endogenous cardiovascular progenitors isolated directly from the heart suggest that cell-based treatment for heart patients using stem cells that reside in the heart provides significant functional benefit and an improvement in patient outcome. Methods to achieve improved engraftment and regeneration may extend this therapeutic benefit. Endogenous cardiovascular progenitors have been tested extensively in small animals to identify cells that improve cardiac function after myocardial infarction. However, the relative lack of large animal models impedes translation into clinical practice. This review will exclusively focus on the latest research pertaining to humans and large animals, including both endogenous and induced sources of cardiovascular progenitors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Japan | 1 | 3% |
United States | 1 | 3% |
Brazil | 1 | 3% |
Unknown | 35 | 92% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 12 | 32% |
Student > Ph. D. Student | 10 | 26% |
Student > Master | 5 | 13% |
Researcher | 4 | 11% |
Professor > Associate Professor | 2 | 5% |
Other | 3 | 8% |
Unknown | 2 | 5% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 14 | 37% |
Medicine and Dentistry | 13 | 34% |
Biochemistry, Genetics and Molecular Biology | 7 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
Economics, Econometrics and Finance | 1 | 3% |
Other | 1 | 3% |
Unknown | 1 | 3% |